The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Is amlodipine more cardioprotective than other antihypertensive drug classes?

  • Park, Chang Gyu (Department of Cardiology, Cardiovascular Center, Korea University Guro Hospital)
  • Received : 2014.04.22
  • Accepted : 2014.04.24
  • Published : 2014.05.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani LG. The pharmacoeconomic impact of amlodipine use on coronary artery disease. Pharmacol Res 2006;54:158-163. https://doi.org/10.1016/j.phrs.2006.04.002
  2. Writing Group Members, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215. https://doi.org/10.1161/CIRCULATIONAHA.109.192667
  3. Rayner M, Petersen S; British Heart Foundation. European Cardiovascular Disease Statistics. 2000 ed. London: British Heart Foundation, 2000.
  4. Korean Statistical Information Service. Statistics Korea: 2013 update [Internet]. Daejeon: Korean Statistical Information Service, 2013 [cited 2013 Sep 25]. Available from: http://kosis.kr/.
  5. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407. https://doi.org/10.1291/hypres.28.385
  6. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens 2014;32:3-15. https://doi.org/10.1097/HJH.0000000000000065
  7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520. https://doi.org/10.1001/jama.2013.284427
  9. Lee SA, Choi HM, Park HJ, Ko SK, Lee HY. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med 2014;29:315-324. https://doi.org/10.3904/kjim.2014.29.3.315
  10. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331. https://doi.org/10.1161/01.CIR.92.5.1326
  11. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009;122:356-365. https://doi.org/10.1016/j.amjmed.2008.09.043
  12. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure- lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535. https://doi.org/10.1016/S0140-6736(03)14739-3
  13. Powles J, Fahimi S, Micha R, et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013;3:e003733. https://doi.org/10.1136/bmjopen-2013-003733
  14. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392. https://doi.org/10.1056/NEJM198808183190701
  15. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail 2013;1:308-314. https://doi.org/10.1016/j.jchf.2013.04.004
  16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9
  17. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens 2014 Feb 15 [Epub]. http://dx.doi.org/10.1016/j.jash.2014.02.004.
  18. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003;23:2155-2163. https://doi.org/10.1161/01.ATV.0000097770.66965.2A
  19. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000;356:366-372. https://doi.org/10.1016/S0140-6736(00)02527-7
  20. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427. https://doi.org/10.1161/01.CIR.0000039288.86470.DD

Cited by

  1. Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study vol.32, pp.3, 2014, https://doi.org/10.3904/kjim.2015.404